COMP <GO>
AMGN vs ABBV // ALTMAN Z-SCORE & DEBT/EQUITY
Amgen Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: AMGN 7
— ABBV 8
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: ABBV
LAST: $466.01 (+1.15%) • MKT CAP: $249.09B
balance-sheet
3.83
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
balance-sheet
5.33
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AMGN VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AMGN | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 67.20% | 70.20% | -3.00 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.50% | 29.00% | -14.50 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 27.2x | 33.3x | -6.10 | AMGN | /valuation <GO> |
| Free Cash Flow Yield | 3.25% | 3.47% | -0.22 | ABBV | /fcf-yield <GO> |
| Operating Margin | 24.70% | 24.60% | +0.10 | AMGN | /operating-margins <GO> |
| Net Profit Margin | 21.00% | 6.90% | +14.10 | AMGN | /net-margins <GO> |
| Revenue Growth (YoY) | 10.00% | 8.60% | +1.40 | AMGN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.06% | 2.27% | -0.21 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 3.83 | 5.33 | -1.50 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | AMGN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 7.40% | -0.90 | AMGN | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 71.4 | 72.8 | -1.35 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.87 | 1.15 | -0.28 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.0x | 113.1x | -83.10 | AMGN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $249.09B | $513.86B | -$264.77B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AMGN REV | ABBV REV | AMGN GROSS % | ABBV GROSS % | AMGN FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $36.75B | $61.16B | 67.2% | 70.2% | $8.10B | $17.82B |
| FY 2024 | $33.42B | $56.33B | 61.5% | 70.0% | $10.39B | $17.83B |
| FY 2023 | $28.19B | $54.32B | 44.0% | 44.0% | $7.20B | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AMGN // BETA 0.87
ABBV // BETA 1.15